Inmune Historical Income Statement

INMB
 Stock
  

USD 9.33  0.03  0.32%   

Historical analysis of Inmune Bio income statement accounts such as Revenues of 150.8 K or Research and Development Expense of 22.2 M can show how well Inmune Bio performed in making a profits. Evaluating Inmune Bio income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Inmune Bio's future profits or losses. Financial Statement Analysis is much more than just reviewing and examining Inmune Bio latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Inmune Bio is a good buy for the upcoming year.
Please see Risk vs Return Analysis.
  

About Inmune Income Statement Analysis

Inmune Bio Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Inmune Bio shareholders. The income statement also shows Inmune investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Inmune Bio Income Statement Chart

Inmune Bio Income Statement is one of the three primary financial statements used for reporting Inmune's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Inmune Bio revenue and expense. Inmune Bio Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Inmune Bio Operating Expenses is projected to increase significantly based on the last few years of reporting. The past year's Operating Expenses was at 29.33 Million. The current year Research and Development Expense is expected to grow to about 22.2 M, whereas Consolidated Income is forecasted to decline to (31.1 M).

Earning Before Interest and Taxes EBIT

Earnings Before Interest and Tax is calculated by adding [TaxExp] and Interest Expense back to Net Income.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Inmune Bio financial statement analysis. It represents the amount of money remaining after all of Inmune Bio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. The portion of profit or loss for the period; net of income taxes; which is attributable to the parent after the deduction of Net Income Available to Non-controlling Interests from Consolidated Income; and before the deduction of Preferred Dividends.

Revenues

Revenues refers to the total amount of money received by Inmune Bio for goods sold or services provided during a certain time period. It also includes all of Inmune Bio sales as well as any other increase in Inmune Bio equity.Revenues are reported on Inmune Bio income statement and calculated before any expenses are subtracted. Amount of Revenue recognized from goods sold; services rendered; insurance premiums; or other activities that constitute an earning process. Interest income for financial institutions is reported net of interest expense and provision for credit losses.
Most accounts from Inmune Bio income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Inmune Bio current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Please see Risk vs Return Analysis.Inmune Bio Operating Expenses is projected to increase significantly based on the last few years of reporting. The past year's Operating Expenses was at 29.33 Million. The current year Research and Development Expense is expected to grow to about 22.2 M, whereas Consolidated Income is forecasted to decline to (31.1 M).
 2010 2021 2022 (projected)
Revenues USD11 K181 K150.84 K
Revenues11 K181 K150.84 K

Inmune Bio income statement Correlations

Inmune Bio Account Relationship Matchups

Inmune Bio income statement Accounts

201720182019202020212022 (projected)
Consolidated Income(831.49 K)(12.44 M)(7.68 M)(12.1 M)(30.34 M)(31.14 M)
Earning Before Interest and Taxes EBIT(831.49 K)(12.44 M)(7.68 M)(12.1 M)(30.34 M)(31.14 M)
Earning Before Interest and Taxes USD(831.49 K)(12.44 M)(7.68 M)(12.1 M)(30.34 M)(31.14 M)
Net Income(831.49 K)(12.44 M)(7.68 M)(12.1 M)(30.34 M)(31.14 M)
Net Income Common Stock(831.49 K)(12.44 M)(7.68 M)(12.1 M)(30.34 M)(31.14 M)
Net Income Common Stock USD(831.49 K)(12.44 M)(7.68 M)(12.1 M)(30.34 M)(31.14 M)
Operating Expenses981.48 K12.44 M7.76 M12.24 M29.33 M31.65 M
Operating Income(981.48 K)(12.44 M)(7.76 M)(12.23 M)(29.15 M)(29.92 M)
Research and Development Expense435.36 K3.35 M3.28 M5.92 M20.54 M22.16 M
Selling General and Administrative Expense546.12 K9.09 M6.02 M6.32 M8.79 M7.61 M
Weighted Average Shares6.56 M8.68 M10.27 M11.99 M16.13 M14.15 M
Weighted Average Shares Diluted6.56 M8.68 M10.27 M11.99 M16.13 M14.15 M

Inmune Bio Investors Sentiment

The influence of Inmune Bio's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Inmune. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Inmune Bio's public news can be used to forecast risks associated with investment in Inmune. The trend in average sentiment can be used to explain how an investor holding Inmune can time the market purely based on public headlines and social activities around Inmune Bio. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Inmune Bio's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Inmune Bio's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Inmune Bio's news discussions. The higher the estimate score, the more favorable is the investor's outlook on Inmune Bio.

Inmune Bio Implied Volatility

    
  135.64  
Inmune Bio's implied volatility exposes the market's sentiment of Inmune Bio stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Inmune Bio's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Inmune Bio stock will not fluctuate a lot when Inmune Bio's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Inmune Bio in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Inmune Bio's short interest history, or implied volatility extrapolated from Inmune Bio options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Inmune Bio using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Note that the Inmune Bio information on this page should be used as a complementary analysis to other Inmune Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Complementary Tools for Inmune Stock analysis

When running Inmune Bio price analysis, check to measure Inmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inmune Bio is operating at the current time. Most of Inmune Bio's value examination focuses on studying past and present price action to predict the probability of Inmune Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inmune Bio's price. Additionally, you may evaluate how the addition of Inmune Bio to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Is Inmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inmune Bio. If investors know Inmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
182.3 M
Quarterly Revenue Growth YOY
39.75
Return On Assets
-0.26
Return On Equity
-0.58
The market value of Inmune Bio is measured differently than its book value, which is the value of Inmune that is recorded on the company's balance sheet. Investors also form their own opinion of Inmune Bio's value that differs from its market value or its book value, called intrinsic value, which is Inmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inmune Bio's market value can be influenced by many factors that don't directly affect Inmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Inmune Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.